Compare Ascendis Pharma A/S (ASND) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bank of Montreal — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bank of Montreal trades at $178.77 (market cap $125.01B). The key difference: Bank of Montreal is far larger — about 7× Ascendis Pharma A/S's market cap, and Bank of Montreal pays a 2.77% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BMO | |
|---|---|---|
Market Cap | $17.74B | $125.01B |
Sector | Health | Financials |
52-Week High | $277.18 | $178.96 |
52-Week Low | $163.32 | $110.44 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BMO trades at $178.96, up 1.3% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 34% YoY net income growth in Q2 2026 and a 25.92% net margin. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings. The company maintains robust cash flow and a solid balance sheet with $84.25B in equity.
Outlook remains positive driven by earnings beats and expansion in metals & mining. Risks include valuation concerns at a P/E of 19.51 and interest rate sensitivity. The stock offers a steady dividend yield, but investors should monitor integration of recent acquisitions and macroeconomic pressures on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
